Statin use and the risk of biochemical recurrence of prostate cancer after definitive local therapy: A meta-analysis of eight cohort studies

BJU International

Volumn 111, Issue 3 B, 2013, Pages

  Scosyrev, Emil ^a   Tobis, Scott ^a   Donsky, Heather ^a   Wu, Guan ^a   Joseph, Jean ^a   Rashid, Hani ^a   Messing, Edward ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

biochemical failure; biochemical recurrence; prostate cancer; statins

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PROSTATE SPECIFIC ANTIGEN; SIMVASTATIN;

ARTICLE; BRACHYTHERAPY; CANCER RECURRENCE; CANCER STAGING; COHORT ANALYSIS; DRUG USE; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HAZARD RATIO; HUMAN; MALE; META ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK ASSESSMENT; SYSTEMATIC REVIEW;

COHORT STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK;

EID: 84874705242     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11527.x     Document Type: Article

References (41)

1. Siegel R, Ward E, Brawley O, Jemal A,. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-36
2. Roy M, Kung HJ, Ghosh PM,. Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins. Am J Cancer Res 2011; 1: 542-61
3. Papadopoulos G, Delakas D, Nakopoulou L, Kassimatis T,. Statins and prostate cancer: molecular and clinical aspects. Eur J Cancer 2011; 47: 819-30
4. Ward S, Lloyd Jones M, Pandor A, et al,. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007; 11: 1-160, iii-iv
5. Bonovas S, Filioussi K, Sitaras NM,. Statin use and the risk of prostate cancer: a meta-analysis of 6 randomized clinical trials and 13 observational studies. Int J Cancer 2008; 123: 899-904
6. Farwell WR, D'Avolio LW, Scranton RE, Lawler EV, Gaziano JM,. Statins and prostate cancer diagnosis and grade in a veterans population. J Natl Cancer Inst 2011; 103: 885-92
7. Boudreau DM, Yu O, Buist DS, Miglioretti DL,. Statin use and prostate cancer risk in a large population-based setting. Cancer Causes Control 2008; 19: 767-74
8. Tan N, Klein EA, Li J, Moussa AS, Jones JS,. Statin use and risk of prostate cancer in a population of men who underwent biopsy. J Urol 2011; 186: 86-90
9. Lehman DM, Lorenzo C, Hernandez J, Wang CP,. Statin use as a moderator of metformin effect on risk for prostate cancer among type 2 diabetic patients. Diabetes Care 2012; 35: 1002-7
10. Breau RH, Karnes RJ, Jacobson DJ, et al,. The association between statin use and the diagnosis of prostate cancer in a population based cohort. J Urol 2010; 184: 494-9
11. Haukka J, Sankila R, Klaukka T, et al,. Incidence of cancer and statin usage-record linkage study. Int J Cancer 2010; 126: 279-84
12. Chang CC, Ho SC, Chiu HF, Yang CY,. Statins increase the risk of prostate cancer: a population-based case-control study. Prostate 2011; 71: 1818-24
13. Coogan PF, Kelly JP, Strom BL, Rosenberg L,. Statin and NSAID use and prostate cancer risk. Pharmacoepidemiol Drug Saf 2010; 19: 752-5
14. Murtola TJ, Tammela TL, Lahtela J, Auvinen A,. Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2007; 16: 2226-32
15. Marcella SW, David A, Ohman-Strickland PA, Carson J, Rhoads GG,. Statin use and fatal prostate cancer: A matched case-control study. Cancer 2012; 118: 4046-52
16. Marubini E, Valsecchi E,. Analysing Survival Data from Clinical Trials and Observational Studies. New York: John Whiley and Sons, 1995
17. Egger M, Smith GD, Schneider M, Minder C,. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34
18. Moyad MA, Merrick GS, Butler WM, et al,. Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer. Urology 2005; 66: 1150-4
19. Moyad MA, Merrick GS, Butler WM, et al,. Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancer. Urol Nurs 2006; 26: 298-303
20. Sharma NK, Ruth K, Horwitz E, et al,. Statin use prior to radiation therapy for prostate cancer does not improve outcome: The Fox Chase Experience. Int J Rad Oncol Biol Phys 2006; 66 (Suppl.): [Abstract]
21. Lavery H, Hobbs A, Ghanaat M,. Preoperative statin use associated with lower PSA but similar histopathologic outcomes. [Abstract 145]. Presented at the AUA Annual Meeting 2011. Available at: http://www.aua2011.org/abstracts/ printpdf.cfm?ID=145. Accessed April 2012
22. Krane LS, Kaul SA, Stricker HJ, Peabody JO, Menon M, Agarwal PK,. Men presenting for radical prostatectomy on preoperative statin therapy have reduced serum prostate specific antigen. J Urol 2010; 183: 118-24
23. Ritch CR, Hruby G, Badani KK, Benson MC, McKiernan JM,. Effect of statin use on biochemical outcome following radical prostatectomy. BJU Int 2011; 108: E211-6
24. Hamilton RJ, Banez LL, Aronson WJ, et al,. Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer 2010; 116: 3389-98
25. Ku JH, Jeong CW, Park YH, Cho MC, Kwak C, Kim HH,. Relationship of statins to clinical presentation and biochemical outcomes after radical prostatectomy in Korean patients. Prostate Cancer Prostatic Dis 2011; 14: 63-8
26. Mondul AM, Han M, Humphreys EB, Meinhold CL, Walsh PC, Platz EA,. Association of statin use with pathological tumor characteristics and prostate cancer recurrence after surgery. J Urol 2011; 185: 1268-73
27. Gutt R, Tonlaar N, Kunnavakkam R, Karrison T, Weichselbaum RR, Liauw SL,. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol 2010; 28: 2653-9
28. Kollmeier MA, Katz MS, Mak K, et al,. Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 2011; 79: 713-8
29. Soto DE, Daignault S, Sandler HM, Ray ME,. No effect of statins on biochemical outcomes after radiotherapy for localized prostate cancer. Urology 2009; 73: 158-62
30. Goldstein MR, Mascitelli L,. Effect of statin use on biochemical outcome following radical prostatectomy. (Editorial). BJU Int 2011; 108: E6-8
31. Montori VM, Smieja M, Guyatt GH,. Publication bias: a brief review for clinicians. Mayo Clin Proc 2000; 75: 1284-88
32. Thornton A, Lee P,. Publication bias in meta-analysis: its causes and consequences. J Clin Epidemiol 2000; 53: 207-16
33. Boorjian SA, Thompson RH, Tollefson MK, et al,. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol 2011; 59: 893-9
34. Alizadeh M, Sylvestre MP, Zilli T, et al,. Effect of statins and anticoagulants on prostate cancer aggressiveness. Int J Radiat Oncol Biol Phys 2012; 83: 1149-53
35. Akduman B, Tandberg DJ, O'Donnell CI, Hughes A, Moyad MA, Crawford ED,. Effect of statins on serum prostate-specific antigen levels. Urology 2010; 76: 1048-51
36. Hamilton RJ, Goldberg KC, Platz EA, Freedland SJ,. The influence of statin medications on prostate-specific antigen levels. Natl Cancer Inst 2008; 100: 1511-8
37. Chang SL, Harshman LC, Presti JC Jr,. Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination Survey. J Clin Oncol 2010; 28: 3951-7
38. Niraula S, Pond G, De Wit R, Eisenberger M, Tannock IF, Joshua AM,. Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study. Can Urol Assoc J 2011; 2: 1-8
39. Algotar AM, Thompson PA, Ranger-Moore J, et al,. Effect of aspirin, other NSAIDs, and statins on PSA and PSA velocity. Prostate 2010; 70: 883-8
40. Katz MS, Carroll PR, Cowan JE, Chan JM, D'Amico AV,. Association of statin and nonsteroidal anti-inflammatory drug use with prostate cancer outcomes: results from CaPSURE. BJU Int 2010; 106: 627-32
41. Van Hemelrijck M, Garmo H, Holmberg L, et al,. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. J Clin Oncol 2010; 28: 3448-56